Effect of Ciclesonide on Exercise Induced Bronchoconstriction
Launched by HAMILTON HEALTH SCIENCES CORPORATION · Sep 5, 2007
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
To study the effects of 4 doses of ciclesonide on exercise-induced bronchoconstriction, bronchial responsiveness to mannitol, sputum parameters and other parameters of asthma control in asthmatic patients. The primary aim was to evaluate exercise-induced bronchoconstriction as a method of determining the dose and time responses of inhaled corticosteroid therapy. The secondary aims were to evaluate the dose and time responses of sputum parameters and responsiveness to mannitol to inhaled corticosteroid therapy. Furthermore to explore the relationship(s) between exercise induced bronchoconstr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • stable asthma not on maintenance asthma medications
- • exercise induced bronchoconstriction on dry air exercise challenge.
- Exclusion Criteria:
- • other significant co-morbidity or treatments that might interfere with the conduct or results of the study
- • fail to return to baseline after a maximum washout period of 8 weeks
- • unable to perform the procedures of the study
About Hamilton Health Sciences Corporation
Hamilton Health Sciences Corporation is a leading healthcare provider in Canada, renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on translating scientific discoveries into effective treatments, the organization operates a network of hospitals and specialized centers that facilitate cutting-edge research across various medical disciplines. Hamilton Health Sciences is dedicated to fostering collaboration among researchers, healthcare professionals, and industry partners, ensuring that clinical trials are conducted with the highest ethical standards and rigor. Through its robust research infrastructure, the corporation aims to enhance health outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Paul O'Byrne, MD
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials